Viz.ai is the leader in applied artificial intelligence in healthcare. It was inspired by a patient who underwent a successful brain surgery and yet died because the surgery came too late.
Viz.ai uses deep learning algorithms to identify a suspected large vessel occlusion - a disabling type of stroke - in a CT scan and alerts the stroke team specialist within minutes.
Viz.ai was founded in 2016 in Tel Aviv, Israel, by Chris Mansi, David Golan, & Manoj Ramachandran. The company is headquartered in San Francisco, California, with an office in Tel Aviv, Israel.
Viz.ai’s mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment and improve access to care.
Viz.ai’s flagship product, Viz LVO, leverages advanced deep learning to communicate time-sensitive information about suspected stroke patients straight to a specialist who can intervene and treat.
Viz.ai uses Artificial Intelligence (AI) to synchronize stroke care, thereby reducing time to treatment and expanding patient access to life-saving care.
In February 2018, the U.S. Food and Drug Administration (FDA) granted a De Novo clearance for Viz LVO. Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral perfusion image analysis.
Viz.ai is backed by leading investors, including Kleiner Perkins, Greenoaks, Google Ventures, Innovation Endeavors and others. The company raised $50M from a "Series B" financing on Oct 23, 2019. This brings Viz.ai's total funding to $80.6M to date.
Viz.ai was recognized in the inaugural Forbes AI list as one of America’s 50 Most Promising Artificial Intelligence Companies.